Plus Therapeutics announced on July 31, 2025, that its wholly-owned subsidiary, CNSide Diagnostics, LLC, will make the CNSide cerebrospinal fluid (CSF) assay platform and testing services commercially available in Texas in August 2025. This marks a significant step in the diagnostic's U.S. launch.
The initial commercial focus will be on National Cancer Institute (NCI) Designated Cancer Centers and large private healthcare systems in Texas. These include the University of Texas - Southwestern, MD Anderson Cancer Center, Mays Cancer Center, Baylor Scott & White Health, and Texas Oncology.
The CNSide platform has a proven track record, with more than 11,000 tests performed at over 200 U.S. cancer institutions since 2020. It has demonstrated high sensitivity (92%) and specificity (95%), influencing treatment decisions in over 90% of cases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.